Best Infectious Diseases Companies in San Francisco, United States

Developer of therapeutics for neurology and infectious diseases. It offers a pipeline of drug candidates which include LHP588, is a next-generation gingipain inhibitor for gingivalis infection which causes Alzheimer's disease, Parkinson's disease, and oral dyslapsia. It also offers LHP852 for gingivalis infection and LHP803 for coronavirus infection.

Funding rounds

• Apr 2026Series A$15.2M

Founders & team

Casey LynchChief Executive Officer

Investors

Double Point Ventures

Tech stack

BootstrapGoogle CloudGoogle Cloud CdnGsapHstsHttp/3

Provider of drug discovery services

Jaguar Health is engaged in developing novel, sustainably derived gastrointestinal products for humans and animals. The company focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Canalevia is the company's lead animal prescription drug product candidate intended for the treatment of various forms of diarrhea in dogs and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes.

Funding rounds

• Jan 2026Grant (prize money)$240K
• Sep 2025Post IPO$2.4M
• Feb 2023Post IPO—
• Jul 2022Post IPO$300K

Founders & team

Lisa ConteFounder & CEO

Investors

Sagard Holdings, Hercules Capital, Napo Pharma, FDA

Tech stack

WordpressMysqlPhpBootstrapYoast SeoNginx

Aligos Therapeutics has developed small molecule-based therapeutics for the treatment of hepatologic diseases and viral infections. The drugs target viral nucleic acids, encoded proteins, oncogenes, and resultant proteins for the treatment. It has developed drugs to treat chronic hepatitis B, nonalcoholic steatohepatitis, and hepatocellular carcinoma.

Funding rounds

• Feb 2025Post IPO$105M
• Oct 2023Post IPO$92.2M
• Jan 2020Series B$125M
• 2018Series A$100M

Founders & team

Lawrence BlattCEOMargarita ChavezBoard Member

Investors

Wellington, Boxer Capital, Logos, Vivo Capital, Novo Holdings, Roche

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai

CytoVale is focussed on developing biomarkers for the early detection of sepsis, an infectious reaction that can lead to lung, kidney and liver failure. Its technology is based on the mechanical properties of individual cells (mechanomics). The instrument uses microfluidics to route and physically probe individual cells and claims to have the capacity to measure over 10 biophysical cell markers at rates above 2k cells per second, providing a high-throughput detection of the disease.

Provider of diagnostic solutions for systemic infections. Its proprietary technology, based on research from Stanford University, measures gene expression patterns related to the immune system to diagnose sepsis. It provides products such as InSep for acute infection and sepsis tests, ViraBac for acute infection tests, SARC-CoV-2 swabs, etc.

Funding rounds

• Sep 2024Series E$57M
• Jul 2023Grant (prize money)$299.8K
• Nov 2021Grant (prize money)$12.1M
• Nov 2021Grant (prize money)$1.7M

Founders & team

Jonathan RomanowskyCo-Founder and Chief Business Officer

Investors

GSVP, Khosla Ventures, Think.Health, Northpond Ventures, StartX, DARPA

Tech stack

BootstrapBricksCloudflareCloudflare Bot ManagementContact Form 7Core-Js

Trellis Bioscience is a biotech company that develops human antibodies against infectious diseases and cancer. The company's technology platform, CellSpot, identifies B-cells that produce desirable human antibodies for therapeutic use. The company licensed a pre-IND stage anti-RSV mAb to MedImmune in 2009 and licensed its influenza A and B program to ContraFect in 2014. The company's current lead program is focused on pandemic influenza. The company also has discovered antibodies against following immuno-oncology targets: TIM-3 (T-cell immunoglobulin and mucin domain 3), LAG-3 (Lymphocyte-activation gene 3), KIR (Killer cell immunoglobulin-like receptors), CEACAM (Carcino-Ebryonic Antigen) and B7-H3.

Funding rounds

• Apr 2025Grant (prize money)$297.9K
• Sep 2020Grant (prize money)$3M
• Jan 2020Grant (prize money)$3.2M
• Feb 2016Grant (prize money)$5.8M

Founders & team

Stefan RyserPresident & CEO

Investors

Pac-Link, Easton Capital Investment Group, Morgenthaler, Novartis Venture Fund, CARB-X, HHS

Developer of therapeutics for the treatment of infectious diseases. The company's lead candidate drug is BJT-778, a human anti-HBsAg monoclonal antibody for the restoration of adaptive immunity. Another drug candidate is BJT-754, a small molecule HBsAg inhibitor an oral small molecule drug for HBV infection.

Funding rounds

• May 2024Series C$182M
• Aug 2022Series B$41M
• 2020Series A$20M

Founders & team

Keting ChuFounder

Investors

HBM Healthcare Investments, Arkin Holdings, Octagon Capital Advisors, RiverVest Venture Partners, Novo Holdings, Wellington

Developer of therapeutic solutions for treating malaria and other parasitic diseases

Developer of therapies for treating multiple diseases. The company has developed targeted therapeutics to modulate TMBIM6 an intracellular transmembrane protein. The company has developed a drug pipeline for Oncology, infectious diseases, and Parkinson's disease.

Funding rounds

• Apr 2025Grant (prize money)$299.2K
• Sep 2023Grant (prize money)$999.3K
• Jun 2023Grant (prize money)$348.9K
• Jul 2022Grant (prize money)$97.3K

Founders & team

Scott RobinsonFounder

Investors

MassChallenge, Military Health

Tech stack

WixReactGoogle CloudPolyfillLodashSectigo

Developer of biologics to treat hepatitis B infection. It has clinical programs focused on hepatitis B virus (HBV) infection and immunotherapeutics to treat infectious diseases. It has licensed rights to develop a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in China. It is also developing VIR-2218, an investigational RNA interference (RNAi) therapeutics to treat hepatitis B infection (licensed from Vir Biotechnology).

Funding rounds

• Sep 2021Post IPO$100M
• Mar 2021Series D$155M
• May 2018Series D$260M

Founders & team

Zhi HongCo-Founder & CEO

Investors

Invesco, Lake Bleu Capital, GIC, Yunfeng Capital, Arch Venture Partners, 6 Dimensions Capital

Tech stack

Animate.CssAnime.JsAosApple Icloud MailBootstrapGodaddy

Developer of immunotherapy platform for infectious disease prevention and cancer therapy. It offers T-cell therapy platform for development of therapeutics which include FLOVID-20 for covid, FlowVAx is an Ebola vaccine, FlowVax BreastCA for breast cancers, and FlowVax HPV for HPV-induced cervical and throat cancer.

Funding rounds

• Jul 2024Seed$225K
• Nov 2022Seed$180K
• Mar 2016Seed$2.3M
• Apr 2011Seed$1.1M

Founders & team

Reid RubsamenFounder & CEO

Investors

Button Capital